Eli Lilly and Company (NYSE:LLY) Shares Down 1.4% – What’s Next?

Eli Lilly and Company (NYSE:LLY) shares fell 1.4% on Wednesday . The stock traded as low as $1,204.16 and last traded at $1,218.7560. 2,598,215 shares changed hands during trading, a decline of 19% from the average session volume of 3,224,212 shares. The stock had previously closed at $1,235.56.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bank of America raised its price target on Eli Lilly to $1,334 from $1,251 and reiterated a buy rating, signaling confidence in further upside from current levels. Benzinga article
• Positive Sentiment: JPMorgan and RBC also reportedly lifted their LLY targets, reinforcing Wall Street’s bullish stance on Lilly’s growth outlook and drug demand. TheStreet article
• Positive Sentiment: New coverage highlighted record GLP-1 usage and accelerating sales of Lilly’s best-selling obesity and diabetes medicines, supporting expectations for strong revenue growth. Motley Fool article
• Positive Sentiment: Lilly announced progress in its neuropathic pain program, with a Phase 2 trial reaching completion, adding to the company’s pipeline momentum beyond GLP-1 drugs. TipRanks article
• Positive Sentiment: Lilly said it will present 16 abstracts at AAIC 2026, including new Alzheimer’s diagnostic and therapeutic data, which could broaden investor confidence in its longer-term growth pipeline. PR Newswire article
• Neutral Sentiment: Several market commentary pieces noted that biotech and Lilly remain among the market’s stronger growth names, with mutual funds and strategists showing continued interest in the sector. Zacks article
• Negative Sentiment: Tampa General Hospital sued Eli Lilly over allegedly pulling 340B discounts, creating a legal/regulatory overhang that could pressure sentiment if the dispute escalates. Healthcare Finance News article

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LLY. Truist Financial boosted their target price on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the stock a “buy” rating in a research report on Wednesday. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 8th. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a report on Monday. UBS Group set a $1,370.00 price objective on shares of Eli Lilly and Company in a research note on Thursday. Finally, Royal Bank Of Canada raised their target price on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,263.41.

Eli Lilly and Company Stock Down 2.3%

The firm has a 50-day moving average of $1,091.91 and a two-hundred day moving average of $1,032.43. The stock has a market capitalization of $1.12 trillion, a price-to-earnings ratio of 42.24, a price-to-earnings-growth ratio of 1.51 and a beta of 0.51. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period last year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 35.81 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently modified their holdings of the stock. JFS Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 20.6% during the 2nd quarter. JFS Wealth Advisors LLC now owns 901 shares of the company’s stock valued at $1,081,000 after acquiring an additional 154 shares in the last quarter. Tema ETFs LLC increased its stake in shares of Eli Lilly and Company by 5.6% in the second quarter. Tema ETFs LLC now owns 25,006 shares of the company’s stock worth $29,993,000 after acquiring an additional 1,321 shares during the last quarter. Peirce Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 6.9% during the second quarter. Peirce Capital Management LLC now owns 403 shares of the company’s stock worth $483,000 after acquiring an additional 26 shares in the last quarter. West Branch Capital LLC boosted its position in Eli Lilly and Company by 2.1% during the second quarter. West Branch Capital LLC now owns 8,703 shares of the company’s stock valued at $10,439,000 after purchasing an additional 178 shares during the last quarter. Finally, Canvas Wealth Advisors LLC boosted its position in Eli Lilly and Company by 4.1% during the second quarter. Canvas Wealth Advisors LLC now owns 1,493 shares of the company’s stock valued at $1,791,000 after purchasing an additional 59 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.